Technology transfer

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Retrieved on: 
Tuesday, December 14, 2021
Technology transfer, Solution, CEO, CEUS, Group, Gadolinium, Head, Breast, Agent handling, Risk, R, Software, Patient, Human, Forward-looking statement, Neck, Food, Artificial intelligence, Research and development, Magnetic resonance imaging, Pelvis, United Kingdom, Euronext Paris, Union, Trial of the century, 3D ultrasound, European Medicines Agency, AI, Abdomen, Research, MRI, Central nervous system, Google Images, UNIK, US Foods, Safety, GBT, Thorax, Nuclear medicine, AMF, Pharmaceutical industry, Medical imaging, Medical device, Risk management, Guerbet, EU

MILAN, Italy, Dec. 14, 2021 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, and Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, today announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent. This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names. The companies will also collaborate on manufacturing, as well as research and development for future indications. Financial terms of the transaction are not disclosed.

Key Points: 
  • This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names.
  • Both Guerbet and Bracco Imaging each own valuable intellectual property relating to Gadopiclenol.
  • Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities.
  • Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine.

Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol

Retrieved on: 
Tuesday, December 14, 2021
Technology transfer, Solution, CEO, CEUS, Group, Gadolinium, Head, Breast, Agent handling, Risk, R, Software, Patient, Human, Forward-looking statement, Neck, Food, Artificial intelligence, Research and development, Magnetic resonance imaging, Pelvis, United Kingdom, Euronext Paris, Union, Trial of the century, 3D ultrasound, European Medicines Agency, AI, Abdomen, Research, MRI, Central nervous system, Google Images, UNIK, US Foods, Safety, GBT, Thorax, Nuclear medicine, AMF, Pharmaceutical industry, Medical imaging, Medical device, Risk management, Guerbet, EU

MILAN, Italy, Dec. 14, 2021 /PRNewswire/ -- Guerbet (FR0000032526 GBT), a global leader in medical imaging offering a comprehensive range of pharmaceutical products, medical devices, and digital and artificial intelligence (AI) solutions for diagnostic and interventional imaging, and Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, today announced they have signed a global collaboration for Gadopiclenol, a next-generation magnetic resonance imaging (MRI) contrast agent. This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names. The companies will also collaborate on manufacturing, as well as research and development for future indications. Financial terms of the transaction are not disclosed.

Key Points: 
  • This global collaboration will result in Guerbet and Bracco Imaging commercializing the product independently under different brand names.
  • Both Guerbet and Bracco Imaging each own valuable intellectual property relating to Gadopiclenol.
  • Bracco Imaging S.p.A. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities.
  • Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine.

Air Force Selects MYRADAR For Development of Technologies For Use in Nuclear Non-Proliferation Monitoring

Retrieved on: 
Thursday, December 9, 2021
Transfer, Rhea, ISR, STTR, Joint, Research, JCPOA, GLOBE, Astrophysics, Small Business Innovation Research, Technology, Climate change, Planetary science, HAND, Professor, Joint Comprehensive Plan of Action, Maximal and minimal elements, Technology transfer, RSA, Machine learning, Air force, Intelligence, LLC, ACME, Program, United, Algorithm, Medical imaging

In addition to remote sensing capabilities, the HAND instrumentation payload will provide in-situ measurements as a high-sensitivity ground-truth smoking gun for specific species of interest.

Key Points: 
  • In addition to remote sensing capabilities, the HAND instrumentation payload will provide in-situ measurements as a high-sensitivity ground-truth smoking gun for specific species of interest.
  • The addition of high sensitivity in-situ spectral capabilities complements the broader remote detection capabilities.
  • One of our group's strengths is the development of aircraft instrumentation to better understand our atmosphere, said Daniel Cziczo, Professor and Head of Purdues Department of Earth, Atmospheric and Planetary Sciences.
  • This project will give us a chance to leverage our expertise in instrument development and atmospheric measurements to improve global safety.

Renova Therapeutics Appoints Dr. Vijay Mahant as Its CEO

Retrieved on: 
Thursday, December 9, 2021
Physician, Translational medicine, Loughborough University, GLOBE, Knowledge, Biotechnology, University of Texas Health Science Center at San Antonio, Longevity, IP, Quality of life, Stanford University, Patient, Therapy, CEO, Journal, Technology transfer, Diabetes, CHF, Advisory, R, Renova, Heart, University, University of Texas at Austin, Intellectual property, FDA, UCSD, Conditional sentence, Roy Taylor (scientist), Journal of Translational Medicine, Degenerative disease, IND, Pharmaceutical industry

CARLSBAD, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Dr. Mahant brings a wealth of knowledge and experience to his role as the CEO.

Key Points: 
  • CARLSBAD, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Dr. Mahant brings a wealth of knowledge and experience to his role as the CEO.
  • Dr. Mahant stated: "I am thrilled and honored to accept the role of CEO at Renova Therapeutics.
  • Renova Therapeutics' cutting-edge proprietary paracrine gene therapy platform is potentially a "game-changer" for patients by improving quality of life and longevity.
  • Renova Therapeutics has assembled a world-class team of physicians, scientists, regulatory experts, a quality management system expert, clinical trial experts and business development leaders.

Purple Biotech Appoints Senior Business Development Executive Fabien Sebille as Chief Business Officer

Retrieved on: 
Thursday, December 9, 2021
Transfer, U.S. Securities and Exchange Commission, CM24, Pancreatic cancer, STAT3, State, Company, Forward-looking statement, Business development, SEC, University technology transfer offices, GLOBE, Therapy, University of Nantes, Celecoxib, Cancer, Infection, Drug resistance, Intention, Private Securities Litigation Reform Act, Medical Research Council (United Kingdom), PD-1, Drug development, Food, Hypertension, Patient, Nivolumab, Technology transfer, Large-cell lung carcinoma, Head, CEACAM1, Doctor of Philosophy, OSE, University, Patent, FDA, Legislation, Survival, Marketing, SCCHN, Bristol Myers Squibb, Regulation of tobacco by the U.S. Food and Drug Administration, Annual report, Medical Research Council, Imperial College London, Biotechnology, Cetuximab, Risk, Pharmaceutical industry

REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Fabien Sebille, Ph.D., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its Chief Business Officer.

Key Points: 
  • REHOVOT, Israel, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, today announced the appointment of Fabien Sebille, Ph.D., a senior business development executive with more than 15 years of professional experience in the biotechnology industry, as its Chief Business Officer.
  • Previously, Dr. Sebille served as Executive Director of Business Development and in different senior business development positions, at Debiopharm International SA, a Swiss-based privately-held biopharmaceutical company focused on drug development in oncology and infectious diseases.
  • Fabiens deep scientific background, strong understanding of the biotechnology industry and vast business development experience are ideally suited for the newly created role of Chief Business Officer at Purple Biotech, said Mr. Gil Efron, Purple Biotechs President and Chief Financial Officer.
  • We are thrilled to welcome him to the team and look forward to Fabien leading our business development activities.

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

Retrieved on: 
Thursday, December 9, 2021
Company, Event, GLOBE, Date-time group, Annual general meeting, ESMO, Intention, DNA, Phenotype, Patient, Technology transfer, GMP, Immunotherapy, Poster, NASDAQ, NSCLC, SITC, ACHL, Society for Immunotherapy of Cancer, Pharmaceutical industry, Vaccine, Online gambling

LONDON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today presented positive data at the ESMO Immuno-Oncology Congress 2021 (ESMO I-O) that further demonstrate that Achilles’ VELOS™ Process 2 manufacturing increases clonal neoantigen-reactive T cell (cNeT) doses by more than 10-fold over Process 1 at GMP scale and maintains a highly potent polyclonal phenotype. These data add to the pilot scale proof-of-concept study recently reported at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Key Points: 
  • These data add to the pilot scale proof-of-concept study recently reported at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
  • These Process 2 GMP data validate our previously reported R&D data and confirm retention of critical phenotypic characteristics and the ability to identify the active drug component of our products without adding to end-to-end manufacturing time.
  • Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell.
  • Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Physician, Forward-looking statement, Company, Neoplasm, Population, GLOBE, SEC, Technology, NGS, West Pharmaceutical Services explosion, OCX, Failure, Lung cancer, Patient, Industry, Technology transfer, Cancer, Accounting, Partnership, Certification, Incidence, Maintenance, COVID-19, RNA, Program, Intellectual property, Goal, Diagnosis, Nasdaq, NSCLC, Tumor microenvironment, CTO, Pharmaceutical industry

Per the agreement, Burning Rock has licensed Oncocytes proprietary risk stratification DetermaRx test in China, and is now poised to launch the test to the worlds largest early-stage lung cancer market.

Key Points: 
  • Per the agreement, Burning Rock has licensed Oncocytes proprietary risk stratification DetermaRx test in China, and is now poised to launch the test to the worlds largest early-stage lung cancer market.
  • Under the terms of the revised Exclusive Sublicense Agreement, Oncocyte has achieved part two of the three-part technology transfer, which enables Burning Rock to launch the DetermaRx risk stratification test commercially.
  • This part of the technology transfer included validation that DetermaRx test results achieved in Oncocytes diagnostic laboratory can be reproduced in Burning Rocks diagnostic laboratories.
  • The milestone payment to Oncocyte is subject to Burning Rock confirming completion of this final part of the technology transfer by April 30, 2022.

The University of Colorado Anschutz Medical Campus and Orange Grove Bio to Collaborate on Development and Commercialization of Novel Therapies

Retrieved on: 
Wednesday, December 8, 2021
Aurora, Children's Hospital Colorado, OGB, Medicine, Entrepreneurship, Research, University, Laboratory, Health, GLOBE, Therapy, Growth, Lists of diseases, Drug development, University of Colorado Hospital, Faculty, Patient, Technology transfer, Cancer, Partnership, Inflammation, University of Colorado Denver, Doctor of Philosophy, CU, Education, Autoimmunity, Adult, Student, Toxicology, Pharmaceutical industry

As part of this effort, Orange Grove and CU Anschutz will support educational programming and entrepreneurial initiatives for CU Anschutz researchers, including faculty and students.

Key Points: 
  • As part of this effort, Orange Grove and CU Anschutz will support educational programming and entrepreneurial initiatives for CU Anschutz researchers, including faculty and students.
  • "Our collaboration with Orange Grove Bio will support further development of promising technologies from academia, with the goal of bringing significant life-changing therapies to patients."
  • Orange Grove Bio fosters strong relationships with technology transfer offices outside of the traditional medical technology hubs of Boston and San Francisco.
  • The University of Colorado Anschutz Medical Campusis a world-class medical destination at the forefront of transformative science, medicine, educationand patient care.

Universal Display Corporation Named to Newsweek’s America’s Most Responsible Companies 2022

Retrieved on: 
Tuesday, December 7, 2021
Research, Professional Services, Hardware, Consumer Electronics, Alternative Energy, Energy, Technology, Environment, Semiconductor, Science, Nanotechnology, Finance, U.S. Securities and Exchange Commission, Environment, Company, Research, ESG, Universal Display Corporation, Culture, Growth, Security (finance), Lighting, Newsweek, OLED, Private Securities Litigation Reform Act, Problem solving, Corporate social responsibility, Industry, Form, Social responsibility, Technology transfer, UDC, Sustainability reporting, Mission statement, Nasdaq, Television

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED technology and materials, announced today that the Company was named to Newsweeks list of America's Most Responsible Companies 2022 for the second consecutive year.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED technology and materials, announced today that the Company was named to Newsweeks list of America's Most Responsible Companies 2022 for the second consecutive year.
  • Universal Display ranked #225 on the 2022 list, which recognizes the top 500 most responsible companies in the United States across fourteen different industry subcategories.
  • We are pleased to be ranked for the second year among Americas most responsible companies, said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation.
  • Universal Display Corporation and the Universal Display Corporation logo are trademarks or registered trademarks of Universal Display Corporation.

IDBS and Synthace announce strategic partnership to streamline bioprocess data management

Retrieved on: 
Tuesday, December 7, 2021
Research, Biotechnology, Technology, Investigational New Drug, Metadata, Data analysis, Food, CEO, Decision-making, Organization, Technology transfer, Partnership, Bioreactor, R, Intelligence, General manager, IDBS, Doctor of Philosophy, Solution, Biology, LONDON, IND, Fine chemical

Polar HTPD, powered by Synthace, helps bioprocess development teams adopt faster throughput approaches and significantly shorten timelines by supporting better decision making with more reliable data sets, rich data analysis and modern enterprise data management.

Key Points: 
  • Polar HTPD, powered by Synthace, helps bioprocess development teams adopt faster throughput approaches and significantly shorten timelines by supporting better decision making with more reliable data sets, rich data analysis and modern enterprise data management.
  • "Speed and improved outcomes are what our customers care about during the development of novel biotherapeutics," said Christian Marcazzo, Vice President & General Manager, IDBS.
  • Our partnership with Synthace provides faster time-to-value with embedded integrations between laboratory systems and our enterprise cloud platform for biologics R&D."
  • We're excited to extend the reach of our unique technology to Polar users through our partnership with leading innovator, IDBS."